Intelligence · Clinical Development
Pipeline search results
Programs matching “adc” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 48 pipeline programs matching "adc" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Household-based water treatment with NADCC tablets
United Therapeutics Europe Ltd
Diarrhoea
1 trial -
Loncastuximab Tesirine
ADC Therapeutics SA
Relapsed Diffuse Large B-Cell Lymphoma
1 trial -
Odronextamab
ADC Therapeutics SA
B-cell Non Hodgkin Lymphoma
1 trial -
AAV2-hAADC
PTC THERAPEUTICS, INC.
Aromatic Amino Acid Decarboxylase Deficiency
1 trial -
ADCETRIS 50 mg powder for concentrate for solution for infusion
Takeda
Hodgkin lymphoma (HL) - Hodgkin lymphoma (HL), a neoplasm of lymphoid tissue which is histopathologically defined by the presence of malignant Hodgkin Reed-Sternberg (HRS) cells in a background of inflammatory cells. The proposed pediatric study has been designed to evaluate brentuximab vedotin as a component of a multiagent frontline chemotherapy regimen in patients with advanced stage, newly diagnosed HL, here defined as Stage III and Stage IV and a ≥50 Lansky Play-Performance or Karnofsky Performance Status.
1 trial -
ADCT-301
ADC Therapeutics SA
Acute Myeloid Leukemia (AML)
1 trial -
ADCT-602
ADC Therapeutics SA
Blasts 5 Percent or More of Bone Marrow Nucleated Cells
1 trial -
Adcetris-Levact
Takeda
Clinical Efficacy
1 trial -
CETUXIMAB for ADCC, Colorectal Cancer
Fondazione Telethon ETS
ADCC, Colorectal Cancer
1 trial -
Camidanlumab Tesirine
ADC Therapeutics SA
Relapsed Hodgkin Lymphoma
1 trial -
Cyclophosphamide
ADC Therapeutics SA
Double-Expressor Lymphoma
1 trial -
Eladocagene Exuparvovec
PTC THERAPEUTICS, INC.
AADC Deficiency
1 trial -
Epcoritamab
ADC Therapeutics SA
Large B-cell Lymphoma
1 trial -
Loncastuximab Tesirine
ADC Therapeutics SA
Relapsed or Refractory Large B-cell Lymphoma
1 trial -
Loncastuximab Tesirine
ADC Therapeutics SA
Relapsed Follicular Lymphoma
1 trial -
Loncastuximab Tesirine
ADC Therapeutics SA
Waldenstrom Macroglobulinemia
1 trial -
Loncastuximab Tesirine
ADC Therapeutics SA
Diffuse Large B-cell Lymphoma
4 trials -
Loncastuximab tesirine
ADC Therapeutics SA
Post-transplant Lymphoproliferative Disorder
1 trial -
Loncastuximab tesirine
ADC Therapeutics SA
Diffuse Large B-Cell Lymphoma Refractory
1 trial -
Loncastuximab tesirine
ADC Therapeutics SA
Follicular Lymphoma
1 trial -
Loncastuximab tesirine 150 µg/Kg
ADC Therapeutics SA
Marginal Zone Lymphoma
1 trial -
RC48- ADC
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
1 trial -
RC48-ADC
Chinese University of Hong Kong
Muscle Invasive Bladder Carcinoma
1 trial -
gene therapy
PTC THERAPEUTICS, INC.
Aromatic L-amino Acid Decarboxylase (AADC) Deficiency
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.